RESUMEN
OBJECTIVES: This study was aimed to evaluate the protective effects of phenylethanoid glycosides extract from Cistanche deserticola against atherosclerosis and its molecular mechanism. METHODS: Total phenylethanoid glycosides were extracted and purified from C. deserticola, and the C. deserticola extract (CDE) was used to treat a mice model of atherosclerosis. KEY FINDINGS: CDE containing 81.00% total phenylethanoid glycosides, with the contents of echinacoside and acteoside being 31.36% and 7.23%, respectively. A 13-week of CDE supplementation (1000 mg/kg body weight/day) significantly reduced atherosclerotic lesions in the aortic sinus and entire aorta in ApoE-/- mice fed with a high-fat diet. In addition, varying doses of CDE (250, 500 and 1000 mg/kg body weight/day) lowered plasma total cholesterol, triglyceride and non-high-density lipoprotein cholesterol levels. Transcriptomic analysis of the small intestine revealed the changes enriched in cholesterol metabolic pathway and the activation of Abca1 gene. Further validation using real-time quantitative PCR and western blot confirmed that CDE significantly increased the mRNA levels and protein expressions of ABCA1, LXRα and PPARγ. CONCLUSIONS: Our results demonstrate the beneficial effects of C. deserticola on atherosclerotic plaques and lipid homeostasis, and it is, at least partially, by activating PPARγ-LXRα-ABCA1 pathway in small intestine.
Asunto(s)
Aterosclerosis , Cistanche , Glicósidos , Animales , Ratones , Apolipoproteínas/metabolismo , Apolipoproteínas E/genética , Apolipoproteínas E/metabolismo , Aterosclerosis/tratamiento farmacológico , Aterosclerosis/prevención & control , Transportador 1 de Casete de Unión a ATP/efectos de los fármacos , Transportador 1 de Casete de Unión a ATP/metabolismo , Peso Corporal , Colesterol/metabolismo , Cistanche/química , Glicósidos/química , Glicósidos/farmacología , Ratones Noqueados para ApoE , Extractos Vegetales/química , Extractos Vegetales/farmacología , PPAR gamma/efectos de los fármacos , PPAR gamma/metabolismo , Receptores X del Hígado/efectos de los fármacos , Receptores X del Hígado/metabolismoRESUMEN
Arctium lappa (A. lappa) leaves are widely used in various traditional Chinese herbal formulae to ameliorate atherosclerosis (AS) and its complications such as stroke; however, there is no literature reporting the anti-atherosclerotic effect and mechanism of A. lappa leaves thus far. In the present study, we used network pharmacology and molecular docking approaches to examine the protective effect and potential mechanism of A. lappa leaves against AS in vivo and in vitro. From the network pharmacology, PPARG, HMGCR and SREBF2 were identified as the core targets of A. lappa leaves against AS. Further enrichment analyses of GO and KEGG pathways suggested that A. lappa leaves might play an anti-AS role by regulating metabolic processes and PPAR signalling pathways. The results of molecular docking experiment revealed that the major components of A. lappa leaves interacted with cholesterol efflux-regulating core proteins (PPARG, LXRα, ABCA1, and ABCG1), AMPK and SIRT1. Both in vivo and in vitro experimental results demonstrated that treatment with A. lappa leaves significantly lowered TC and LDL-C, increased HDL-C, and reduced cholesterol accumulation in the liver and aorta of the AS rat model and the foam cell model. Importantly, both in vivo and in vitro experimental results demonstrated that A. lappa leaves regulate the activity of the PPARG/LXRα signalling and AMPK/SIRT1 signalling pathways. Moreover, after treatment with the AMPK inhibitor Compound C in vitro, the improvement induced by A. lappa leaves was significantly reversed. In conclusion, A. lappa leaves attenuated AS-induced cholesterol accumulation by targeting the AMPK-mediated PPARG/LXRα pathway and promoting cholesterol efflux.
Asunto(s)
Arctium , Aterosclerosis , Proteínas Quinasas Activadas por AMP/efectos de los fármacos , Proteínas Quinasas Activadas por AMP/metabolismo , Transportador 1 de Casete de Unión a ATP/metabolismo , Animales , Arctium/química , Aterosclerosis/tratamiento farmacológico , Aterosclerosis/metabolismo , Colesterol/metabolismo , Medicamentos Herbarios Chinos/farmacología , Medicamentos Herbarios Chinos/uso terapéutico , Receptores X del Hígado/efectos de los fármacos , Receptores X del Hígado/metabolismo , Simulación del Acoplamiento Molecular , Farmacología en Red/métodos , PPAR gamma/efectos de los fármacos , PPAR gamma/metabolismo , Ratas , Sirtuina 1/metabolismoRESUMEN
Phytosterols have been shown to improve blood lipid levels and treat atherosclerosis. This research investigated the effects of phytosterol Alisol B 23-acetate (AB23A) on jejunum lipid metabolism and atherosclerosis. The results show that intragastric administration of AB23A can significantly reduce atherosclerotic plaque area and lipid accumulation in the jejunum of ovariectomized ApoE-/- mice fed a high-fat diet and can also improve the lipid mass spectra of the plasma and jejunum. In vitro studies have shown that AB23A can increase cholesterol outflow in Caco-2 cells exposed to high fat concentrations and increase the expression of ATP-binding cassette transfer proteins G5/G8 (ABCG5/G8), the liver X receptor α (LXRα). Furthermore, inhibition of LXRα can significantly eliminate the active effect of AB23A on decreasing intracellular lipid accumulation. We also confirmed that AB23A has a negative effect on Acyl-CoA cholesterol acyltransferase 2 (ACAT2) in Caco-2 cells cultured in the high concentrations of fat, and we found that AB23A further reduces ACAT2 expression in cells treated with the ACAT2 inhibitor pyripyropene or transfected with ACAT2 siRNA. In conclusion, we confirmed that AB23A can reduce the absorption of dietary lipids in the jejunum by affecting the LXRα-ACAT2-ABCG5/G8 pathway and ultimately exert an anti-atherosclerotic effect.
Asunto(s)
Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 5/efectos de los fármacos , Transportador de Casete de Unión a ATP, Subfamilia G, Miembro 8/efectos de los fármacos , Aterosclerosis/metabolismo , Colestenonas/farmacología , Yeyuno/efectos de los fármacos , Lipoproteínas/efectos de los fármacos , Placa Aterosclerótica/metabolismo , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 5/metabolismo , Transportador de Casete de Unión a ATP, Subfamilia G, Miembro 8/metabolismo , Animales , Aorta/efectos de los fármacos , Aorta/metabolismo , Aorta/patología , Aterosclerosis/patología , Células CACO-2 , Colesterol/metabolismo , Ésteres del Colesterol/metabolismo , Dieta Alta en Grasa , Femenino , Glicerofosfolípidos/metabolismo , Humanos , Yeyuno/metabolismo , Yeyuno/patología , Gotas Lipídicas/efectos de los fármacos , Gotas Lipídicas/metabolismo , Gotas Lipídicas/patología , Metabolismo de los Lípidos/efectos de los fármacos , Lipoproteínas/metabolismo , Receptores X del Hígado/efectos de los fármacos , Receptores X del Hígado/metabolismo , Ratones , Ratones Noqueados para ApoE , Ovariectomía , Placa Aterosclerótica/patología , Esterol O-Aciltransferasa/efectos de los fármacos , Esterol O-Aciltransferasa/metabolismo , Triglicéridos/metabolismo , Esterol O-Aciltransferasa 2RESUMEN
BACKGROUND: There is a causative relation between the increased hepatic steatohepatitis prevalence and sweeteners intake, fructose in particular. Despite an increasing understanding of the mechanisms of nonalcoholic steatohepatitis (NASH) pathogenesis, there are no drugs approved for it. OBJECTIVES: Evaluate the effect of bee venom (BV) treatment on the fructose-induced NASH in rats and demonstrate its possible molecular mechanisms. METHODS: NASH was induced in rats by 10% fructose in drinking water for 8 weeks. BV was administered (0.1 mg/kg, i.p.) 3 times per week during the last 2 weeks of the experiment. Sera were used for the determination of lipids, cholesterol, glucose, insulin, and liver enzymes. Hepatic gene expressions of farnesoid X receptor (FXR)α and the liver X receptor (LXR) were determined. Hepatic sterol regulatory element-binding protein (SREBP)1/2, oxidative stress, and inflammation parameters were measured. Liver parts were used for histopathological examination. Small intestine was removed for the determination of tight junction proteins. RESULTS: Fructose caused overt histological damage in the liver, and this was associated with parallel changes in all parameters measured. BV effectively prevented these changes, presumably through amelioration of hepatic SREBP1/2, LXR, and FXRα expression as well as intestinal tight junction proteins. CONCLUSION: These findings support the therapeutic usefulness of BV, a remedy with a favorable safety profile, in the prevention of fructose-induced NASH.
Asunto(s)
Venenos de Abeja/farmacología , Hígado/efectos de los fármacos , Hígado/metabolismo , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Enfermedad del Hígado Graso no Alcohólico/prevención & control , Animales , Venenos de Abeja/administración & dosificación , Modelos Animales de Enfermedad , Fructosa/farmacología , Glucosa/metabolismo , Insulina/metabolismo , Metabolismo de los Lípidos/efectos de los fármacos , Hígado/patología , Pruebas de Función Hepática , Receptores X del Hígado/biosíntesis , Receptores X del Hígado/efectos de los fármacos , Masculino , Enfermedad del Hígado Graso no Alcohólico/sangre , Enfermedad del Hígado Graso no Alcohólico/inducido químicamente , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Wistar , Receptores Citoplasmáticos y Nucleares/biosíntesis , Receptores Citoplasmáticos y Nucleares/efectos de los fármacos , Proteína 1 de Unión a los Elementos Reguladores de Esteroles/efectos de los fármacos , Proteína 2 de Unión a Elementos Reguladores de Esteroles/efectos de los fármacos , Proteínas de Uniones Estrechas/efectos de los fármacosRESUMEN
Intracerebral hemorrhage (ICH) causes neurological function deficit due to the loss of neurons surrounding the hematoma. Increased neurogenesis of endogenous neural stem cells (EnNSCs) is believed to increase cell proliferation and differentiation, thereby improving the neurological deficit. However, there are still limited drugs that are effective for treating neurological deficit. So, the effects of compound K (CK) in EnNSCs were measured after thrombin-induced mice models both in vivo and in vitro, and investigated the probable mechanisms of CK during pro-neurogenesis. The results revealed that 10 µM CK promotes neurogenesis, proliferation and reduces apoptosis of EnNSCs after induction by thrombin. After that, CK treatment increased the neurogenesis of EnNSCs through liver X receptor α (LXRα) signaling pathway using adeno-associated virus knockdown and knocked out mice of LXRα gene. Finally, intraperitoneal injection of 10 mg/kg CK improved the neurogenesis of subventricular zone (SVZ), myelin repair and behavioral deficit after stereotaxic injection of thrombin in the basal ganglia of mice, and this process involved LXRα. These observations provided evidence regarding the effect of CK in pro-neurogenesis via LXRα activation, and suggested further evaluation of it due to its potential role as an effective modulator in the treatment of ICH.
Asunto(s)
Ginsenósidos/farmacología , Receptores X del Hígado/efectos de los fármacos , Red Nerviosa/lesiones , Células-Madre Neurales/efectos de los fármacos , Neurogénesis/efectos de los fármacos , Trombina/farmacología , Animales , Bromodesoxiuridina/metabolismo , Bromodesoxiuridina/farmacología , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Receptores X del Hígado/metabolismo , Ratones Endogámicos C57BL , Ratones Noqueados , Células-Madre Neurales/citología , Trombina/metabolismoRESUMEN
Eight new diketopiperazine-type alkaloids including four oxepin-containing diketopiperazine-type alkaloids, oxepinamides H-K (1-4), and four 4-quinazolinone alkaloids, puniceloids A-D (5-8), together with two known analogues (9 and 10), were isolated from the culture broth extracts of the deep-sea-derived fungus Aspergillus puniceus SCSIO z021. Their structures were elucidated by spectroscopic analyses, and their absolute configurations were determined by Marfey's method along with comparison of their specific rotations and ECD spectra. The absolute configurations of 4 and 5 were further confirmed by a single-crystal X-ray diffraction analysis. Compounds 1-8 showed significant transcriptional activation of liver X receptor α with EC50 values of 1.7-50 µM, and 7 and 8 were the most potent agonists.
Asunto(s)
Alcaloides/química , Aspergillus/química , Dicetopiperazinas/química , Hongos/química , Receptores X del Hígado/efectos de los fármacos , Oxepinas/química , Piperazinas/química , Alcaloides/aislamiento & purificación , Alcaloides/farmacología , Cristalografía por Rayos X , Dicetopiperazinas/aislamiento & purificación , Dicetopiperazinas/farmacología , Estructura Molecular , Oxepinas/sangre , Oxepinas/aislamiento & purificación , Oxepinas/farmacología , Piperazinas/aislamiento & purificación , Piperazinas/farmacologíaRESUMEN
Dendrogenin A (DDA) is a mammalian metabolite that displays anticancer and chemopreventive properties in mice. At the cancer cell level, DDA induces differentiation and death. We investigated herein the nature of DDA cytoxicity in cancer cells. We showed that DDA triggers biochemical and cellular features of macroautophagy/autophagy and that autophagy is cytotoxic. DDA induces both the accumulation of pro-lysosomal sterols and stimulates the expression of regulators of autophagy such as NR4A, LC3 and TFEB through binding to the liver X receptor (LXR), a ligand-dependent transcription factor consisting of 2 isoforms, NR1H2 and NR1H3. These effects are not observed with canonical LXR agonists such as the oxysterol 22(R)-hydroxycholesterol or the synthetic molecules T0901317 and GW3965. DDA effects were measured on melanoma and acute myeloid leukemia cells including patient-derived leukemia cells in vitro and in vivo. Importantly the induction of lethal autophagy kills cells independently of their cytogenetic subgroups and does not differentiate bulk cancer cells from cancer cell progenitors. Together these data show that DDA drives LXR to induce the expression of autophagic genes leading to cancer cells death. This opens up new perspectives for cancer treatment.
Asunto(s)
Apoptosis/efectos de los fármacos , Autofagia/efectos de los fármacos , Benzoatos/farmacología , Bencilaminas/farmacología , Hidrocarburos Fluorados/farmacología , Sulfonamidas/farmacología , Animales , Línea Celular Tumoral , Ligandos , Receptores X del Hígado/efectos de los fármacos , Lisosomas/efectos de los fármacos , Ratones , Neoplasias/tratamiento farmacológicoRESUMEN
NEW FINDINGS: What is the central question of this study? The liver X receptor (LXR) has been reported to regulate several membrane transporters. It is imperative to investigate whether LXR activation regulates SGLT2-mediated glucose transport in human renal proximal tubular cells. What is the main finding and its importance? Liver X receptor activation inhibits SGLT2 transport function in normal and high-glucose conditions via reduction of SGLT2 protein expression. Liver X receptors (LXRs) are members of a nuclear receptor family consisting of two isoforms, LXRα and LXRß. They play a major role in energy metabolism, including lipid and glucose metabolism. Recent studies reported that LXRs regulate plasma glucose, although the mechanism is still uncertain. The present study investigated whether LXR activation regulates sodium glucose cotransporter2 (SGLT2) in human renal proximal tubular cells. LXR agonists, T0901317 and GW3965, inhibited SGLT2-mediated glucose uptake in a concentration-dependent manner. The effect of T0901317 and GW3965 was attenuated by a LXR antagonist, fenofibrate. Activation of the retinoid X receptor (RXR) agonist, bexarotene, potentiates the inhibitory effect of these ligands. Thus, the inhibitory effect of LXR agonists on SGLT2 was mediated and facilitated by LXR and RXR activation, respectively. In addition, the inhibitory effect of LXR agonists was not mediated by cytotoxicity. Exposing HK-2 cells, a renal proximal tubular cell line, to LXR agonists significantly reduced the maximal transport rate of SGLT2 without any effect on transporter affinity. Western blot analysis revealed that LXR activation significantly decreased protein expression of SGLT2 with no change in mRNA level. In addition, LXR activation inhibited canagliflozin-sensitive short-circuit current, which represents SGLT2-mediated glucose transport in a polarized human renal proximal tubular cell monolayer. Furthermore, LXR activation inhibited the transport function of SGLT2 in hyperglycaemic conditions. As such, this study represents evidence for the inhibitory effect of LXR activation on glucose transport in human renal proximal tubular cells.
Asunto(s)
Transporte Biológico/efectos de los fármacos , Hidrocarburos Fluorados/farmacología , Receptores X del Hígado/efectos de los fármacos , Transportador 2 de Sodio-Glucosa/efectos de los fármacos , Sulfonamidas/farmacología , Benzoatos/farmacología , Bencilaminas/farmacología , Proteínas Portadoras/metabolismo , Células Cultivadas , Proteínas de Unión al ADN/metabolismo , Glucosa/metabolismo , Humanos , Receptores Citoplasmáticos y Nucleares/efectos de los fármacos , Transducción de Señal/efectos de los fármacosRESUMEN
Dendrogenin A (DDA) is a newly discovered cholesterol metabolite with tumor suppressor properties. Here, we explored its efficacy and mechanism of cell death in melanoma and acute myeloid leukemia (AML). We found that DDA induced lethal autophagy in vitro and in vivo, including primary AML patient samples, independently of melanoma Braf status or AML molecular and cytogenetic classifications. DDA is a partial agonist on liver-X-receptor (LXR) increasing Nur77, Nor1, and LC3 expression leading to autolysosome formation. Moreover, DDA inhibited the cholesterol biosynthesizing enzyme 3ß-hydroxysterol-Δ8,7-isomerase (D8D7I) leading to sterol accumulation and cooperating in autophagy induction. This mechanism of death was not observed with other LXR ligands or D8D7I inhibitors establishing DDA selectivity. The potent anti-tumor activity of DDA, its original mechanism of action and its low toxicity support its clinical evaluation. More generally, this study reveals that DDA can direct control a nuclear receptor to trigger lethal autophagy in cancers.
Asunto(s)
Antineoplásicos/farmacología , Autofagia/efectos de los fármacos , Colestanoles/farmacología , Imidazoles/farmacología , Leucemia Mieloide Aguda , Receptores X del Hígado/efectos de los fármacos , Melanoma , Animales , Muerte Celular/efectos de los fármacos , Línea Celular Tumoral , Agonismo Parcial de Drogas , Expresión Génica/efectos de los fármacos , Células HEK293 , Células HL-60 , Humanos , Técnicas In Vitro , Receptores X del Hígado/metabolismo , Melanoma Experimental , Proteínas de Transporte de Membrana/efectos de los fármacos , Proteínas de Transporte de Membrana/genética , Ratones , Proteínas Asociadas a Microtúbulos/efectos de los fármacos , Proteínas Asociadas a Microtúbulos/genética , Miembro 1 del Grupo A de la Subfamilia 4 de Receptores Nucleares/efectos de los fármacos , Miembro 1 del Grupo A de la Subfamilia 4 de Receptores Nucleares/genéticaRESUMEN
The aim of this study was to clarify the anti-inflammatory effects and its molecular mechanism of glycyrrhizin on LPS-stimulated human gingival fibroblasts (HGFs), which will be of benefit for periodontitis treatment. An MTT assay was performed to assess the effects of glycyrrhizin on cellular viability. The levels of IL-6 and IL-8 were measured by ELISA. The expression of iNOS, COX-2, NF-κB, and LXRα were detected by western blot analysis. The results showed that glycyrrhizin significantly inhibited LPS-induced IL-6 and IL-8 production, as well as COX-2 and iNOS expression. LPS-induced NF-κB activation in HGFs was also inhibited by treatment of glycyrrhizin. Furthermore, glycyrrhizin increased the expression of LXRα in a concentration-dependent manner. In addition, the inhibition of glycyrrhizin on IL-6 and IL-8 production was reversed by LXRα inhibitor GGPP. In conclusion, these results indicated that glycyrrhizin exhibited its anti-inflammatory effects in HGFs by activating LXRα.
Asunto(s)
Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Encía/efectos de los fármacos , Ácido Glicirrínico/antagonistas & inhibidores , Interleucina-6/metabolismo , Interleucina-8/metabolismo , Lipopolisacáridos/farmacología , Receptores X del Hígado/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Ciclooxigenasa 2/metabolismo , Citocinas/metabolismo , Fibroblastos/patología , Regulación de la Expresión Génica/efectos de los fármacos , Encía/patología , Humanos , FN-kappa B/metabolismo , Óxido Nítrico Sintasa de Tipo II/metabolismo , Periodontitis/tratamiento farmacológico , Transducción de Señal/efectos de los fármacosRESUMEN
In silico screening of DrugBank database to detect liver X receptor (LXR) agonism of marketed drugs using a self-organizing map and successive LXR-Gal4 hybrid reporter gene assay evaluation in vitro discovered alitretinoin and bexarotene as partial liver X receptor agonists. Dose-response curves demonstrated that plasma concentrations observed in clinical trials are sufficient for LXR activation and thus could account for LXR-mediated side-effects such as hypercholesterolemia and hyperlipidemia. The discovered drugs are the first reported dual LXR/RXR agonists and can serve as lead structures for LXR and dual LXR/RXR modulator development.
Asunto(s)
Receptores X del Hígado/efectos de los fármacos , Tetrahidronaftalenos/farmacología , Tretinoina/farmacología , Alitretinoína , Animales , Bexaroteno , Evaluación Preclínica de Medicamentos , Células HEK293 , Humanos , Receptores X del Hígado/genética , RatonesRESUMEN
Liver X receptors (LXRs) including LXRα and LXRß are nuclear receptor transcription factors and play an important role in lipid and glucose metabolism. It has been previously reported that mice lacking LXRß but not LXRα develop a severe urine concentrating defect, likely via a central mechanism. Here we provide evidence that LXRß regulates water homeostasis through increasing aquaporin 2 (AQP2) protein levels in renal collecting ducts. LXRß-/- mice exhibited a reduced response to desmopressin (dDAVP) stimulation, suggesting that the diabetes insipidus phenotype is of both central and nephrogenic origin. AQP2 protein abundance in the renal inner medulla was significantly reduced in LXRß-/- mice but with little change in AQP2 mRNA levels. In vitro studies showed that AQP2 protein levels were elevated upon LXR agonist treatment in both primary cultured mouse inner medullary duct cells (mIMCD) and the mIMCD3 cell line with stably expressed AQP2. In addition, LXR agonists including TO901317 and GW3965 failed to induce AQP2 gene transcription but diminished its protein ubiquitination in primary cultured mIMCD cells, thereby inhibiting its degradation. Moreover, LXR activation-induced AQP2 protein expression was abolished by the protease inhibitor MG132 and the ubiquitination-deficient AQP2 (K270R). Taken together, the present study demonstrates that activation of LXRß increases AQP2 protein levels in the renal collecting ducts via a posttranscriptional mechanism. As such, LXRß represents a key regulator of body water homeostasis.
Asunto(s)
Acuaporina 2/metabolismo , Túbulos Renales Colectores/metabolismo , Receptores X del Hígado/metabolismo , Procesamiento Proteico-Postraduccional , Animales , Fármacos Antidiuréticos/farmacología , Acuaporina 2/genética , Línea Celular , Desamino Arginina Vasopresina/farmacología , Genotipo , Capacidad de Concentración Renal , Túbulos Renales Colectores/efectos de los fármacos , Receptores X del Hígado/deficiencia , Receptores X del Hígado/efectos de los fármacos , Receptores X del Hígado/genética , Ratones Endogámicos C57BL , Ratones Noqueados , Fenotipo , Complejo de la Endopetidasa Proteasomal/metabolismo , Estabilidad Proteica , Proteolisis , Factores de Tiempo , Transfección , Ubiquitinación , Regulación hacia ArribaRESUMEN
Four new pterosin sesquiterpenoids (1-4), a new ent-kaurane diterpenoid (17), and 18 known compounds were isolated from the aerial parts of Pteris cretica L. The structures of the isolates were elucidated based on spectroscopic data analysis, and their absolute configurations were determined by comparison of experimental and calculated electronic circular dichroism spectra. The compounds were evaluated for lipid-lowering effects in 3T3-L1 adipocytes. Compounds 4, 8, 17, and 22 were more potent than the positive control, berberine, in decreasing triglycerides activity, with compound 4 exerting the most potent activity. Compound 4 activated LXRα/ß in a HEK 293T cell-based reporter gene assay. Molecular dynamic simulations revealed that compound 4 activates liver X receptors (LXRs) through hydrogen bonding with the residues of LXRα/ß, suggesting that compound 4 reduces total triglycerides through the regulation of LXRα/ß.
Asunto(s)
Diterpenos de Tipo Kaurano/aislamiento & purificación , Diterpenos de Tipo Kaurano/farmacología , Medicamentos Herbarios Chinos/aislamiento & purificación , Medicamentos Herbarios Chinos/farmacología , Hipolipemiantes/aislamiento & purificación , Hipolipemiantes/farmacología , Indanos/aislamiento & purificación , Indanos/farmacología , Receptores X del Hígado/efectos de los fármacos , Componentes Aéreos de las Plantas/química , Pteris/química , Sesquiterpenos/aislamiento & purificación , Sesquiterpenos/farmacología , Antineoplásicos Fitogénicos/química , Diterpenos de Tipo Kaurano/química , Ensayos de Selección de Medicamentos Antitumorales , Medicamentos Herbarios Chinos/química , Hipolipemiantes/química , Indanos/química , Estructura Molecular , Resonancia Magnética Nuclear Biomolecular , Sesquiterpenos/químicaRESUMEN
Liver X receptor (LXR) agonists have been reported to lower brain amyloid beta (Aß) and thus to have potential for the treatment of Alzheimer's disease. Structure and property based design led to the discovery of a series of orally bioavailable, brain penetrant LXR agonists. Oral administration of compound 18 to rats resulted in significant upregulation of the expression of the LXR target gene ABCA1 in brain tissue, but no significant effect on Aß levels was detected.
Asunto(s)
Encéfalo/metabolismo , Receptores X del Hígado/efectos de los fármacos , Transportador 1 de Casete de Unión a ATP/genética , Transportador 1 de Casete de Unión a ATP/metabolismo , Animales , Masculino , ARN Mensajero/genética , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Regulación hacia ArribaRESUMEN
AIMS: Atherosclerosis is the most common cause of cardiovascular diseases, such as myocardial infarction and stroke. We hypothesized that nagilactone B (NLB), a small molecule extracted from the root bark of Podocarpus nagi (Podocarpaceae), suppresses atherosclerosis in an atherosclerotic mouse model. METHODS AND RESULTS: Male apoE-deficient mice on C57BL/6J background received NLB (10 and 30 mg/kg) for 12 weeks. Compared with the model group, NLB treatment (10 and 30 mg/kg) significantly reduced en face lesions of total aorta areas. In RAW264.7 cells, NLB significantly ameliorated cholesterol accumulation in macrophages via enhancing apolipoprotein A-I and HDL-mediated cholesterol efflux. Mechanistically, NLB induced messenger RNA and protein expression of the ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) in RAW264.7 and THP-1 cells. Liver X receptor (LXR) site mutations in the mouse ABCA1 promoter abrogated NLB-mediated luciferase reporter activity. LXRα and LXRß small interfering RNA suppressed NLB-mediated induction of ABCA1 expression. Consistent with in vitro results, NLB induced ABCA1 expression and suppressed macrophage areas in the aortic sinus. Moreover, NLB treatment did not induce the protein expression of LXR in liver. Hepatic and intestinal cholesterol accumulation was significantly alleviated on NLB treatment. Besides, NLB significantly improved plasma lipid profiles in apoE-deficient mice. CONCLUSION: Selective LXR activation in macrophages with NLB induces ABCA1- and ABCG1-mediated cholesterol efflux while exerting minimal effects on lipogenesis and lipid accumulation in liver, resulting in regression of atherosclerosis, and therefore might be a promising strategy for therapeutics.
Asunto(s)
Aorta/efectos de los fármacos , Enfermedades de la Aorta/prevención & control , Apolipoproteínas E/deficiencia , Aterosclerosis/prevención & control , Diterpenos/farmacología , Hipolipemiantes/farmacología , Receptores X del Hígado/agonistas , Receptores X del Hígado/efectos de los fármacos , Macrófagos/efectos de los fármacos , Transportador 1 de Casete de Unión a ATP/genética , Transportador 1 de Casete de Unión a ATP/metabolismo , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 1/genética , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 1/metabolismo , Animales , Aorta/metabolismo , Aorta/patología , Enfermedades de la Aorta/genética , Enfermedades de la Aorta/metabolismo , Enfermedades de la Aorta/patología , Apolipoproteína A-I/metabolismo , Apolipoproteínas E/genética , Aterosclerosis/genética , Aterosclerosis/metabolismo , Aterosclerosis/patología , Sitios de Unión , Línea Celular Tumoral , HDL-Colesterol/metabolismo , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Predisposición Genética a la Enfermedad , Humanos , Receptores X del Hígado/genética , Macrófagos/metabolismo , Macrófagos/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Mutación , Fenotipo , Placa Aterosclerótica , Regiones Promotoras Genéticas , Células RAW 264.7 , Interferencia de ARN , Transducción de Señal/efectos de los fármacos , TransfecciónRESUMEN
BACKGROUND: We study the effect of liver X receptor ß (LXRß) on ß-amyloid (Aß) peptide generation and autism behaviors by conducting an animal experiment. METHODS: In autistic mice treated with LXRß agonist T0901317, enzyme linked immunosorbent assay was used to measure Aß in brain tissue homogenates. Western blot was used to detect Aß precursors, Aß degradation and secretase enzymes, and expression of autophagy-related proteins and Ras/Raf/Erkl/2 signaling pathway proteins in brain tissue. Changes in autism spectrum disorder syndromes of the BTBR mice were compared before and after T0901317 treatment. RESULTS: Compared with the control group, autistic mice treated with LXRß agonist T0901317 showed significantly lower Aß level in brain tissue (P < 0.05), significantly higher Aß degradation enzyme (NEP, IDE proteins) levels (all P < 0.05), significantly lower Aß secretase enzyme BACE1 protein level (P < 0.05), and significantly lower Ras, P-C-Raf, C-Raf, P-Mekl/2, P-Erkl/2 protein levels (all P < 0.05). BTBR mice treated with T0901317 showed improvements in repetitive stereotyped behavior, inactivity, wall-facing standing time, self-combing time and center stay time, stayed longer in platform quadrant, and crossed the platform more frequently (all P < 0.05). CONCLUSIONS: LXRß could potentially reduce brain Aß generation by inhibiting Aß production and promoting Aß degradation, thereby increasing the expression of autophagy-related proteins, reducing Ras/Raf/Erkl/2 signaling pathway proteins, and improving autism behaviors.
Asunto(s)
Péptidos beta-Amiloides/efectos de los fármacos , Péptidos beta-Amiloides/metabolismo , Trastorno Autístico/tratamiento farmacológico , Hidrocarburos Fluorados/farmacología , Receptores X del Hígado/efectos de los fármacos , Sulfonamidas/farmacología , Análisis de Varianza , Animales , Trastorno Autístico/diagnóstico , Trastorno Autístico/genética , Autofagia , Biomarcadores/análisis , Western Blotting , Modelos Animales de Enfermedad , Regulación hacia Abajo , Ensayo de Inmunoadsorción Enzimática , Regulación de la Expresión Génica , Receptores X del Hígado/genética , Ratones , Ratones Endogámicos C57BL , Distribución Aleatoria , Valores de ReferenciaRESUMEN
CONTEXT: Sea cucumbers have been consumed as tonic, food, and nutrition supplements for many years. OBJECTIVE: The objective of this study is to investigate the antiobesity and lipid-lowering effects of sea cucumber extracts in in vitro and in vivo models and elucidate the mechanism of action of the extracts on obesity and dyslipidemia. MATERIALS AND METHODS: The 60% ethanol extracts from the body walls of 10 different sea cucumbers were investigated for the inhibition of pancreatic lipase (PL) activity in vitro. The optimal active extract (SC-3) was further chemically analyzed by LC-MS and UV. And 0.1% and 0.2% of SC-3 was mixed with a high-fat diet to treat C57/BL6 mice for 6 weeks or 2 weeks as preventive and therapeutic study. The body weight, serum, and liver lipid profile in the mice were investigated. RESULTS: The crude extract of Pearsonothuria graeffei Semper (Holothuriidae) inhibited the PL activity by 36.44% of control at 0.5 µg/mL. SC-3 and echinoside A inhibited PL with an IC50 value at 2.86 µg/mL and 0.76 µM. 0.1% of SC-3 reduced the body weight (23.0 ± 0.62 versus 26.3 ± 0.76 g), the serum TC (2.46 ± 0.04 versus 2.83 ± 0.12 mmol/L), TG (0.19 ± 0.08 versus 0.40 ± 0.03 mmo/L), and LDL-c (0.48 ± 0.02 versus 0.51 ± 0.02 mmol/L), and liver TC (1.19 ± 0.17 versus 1.85 ± 0.13 mmol/mg) and TG (6.18 ± 0.92 versus 10.87 ± 0.97 mmol/mg) contents of the obese C57BL/six mice on a high-fat diet. DISCUSSION AND CONCLUSION: Sea cucumber may be used for developing antiobesity and antihyperlipidemia drugs.
Asunto(s)
Fármacos Antiobesidad/farmacología , Inhibidores Enzimáticos/farmacología , Lipasa/antagonistas & inhibidores , Receptores X del Hígado/efectos de los fármacos , Hígado/efectos de los fármacos , Obesidad/prevención & control , Páncreas/enzimología , Saponinas/farmacología , Pepinos de Mar/metabolismo , Transducción de Señal/efectos de los fármacos , Adipocitos Blancos/efectos de los fármacos , Adipocitos Blancos/metabolismo , Animales , Fármacos Antiobesidad/aislamiento & purificación , Dieta Alta en Grasa , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/aislamiento & purificación , Femenino , Células Hep G2 , Holoturina/análogos & derivados , Holoturina/farmacología , Humanos , Absorción Intestinal/efectos de los fármacos , Lipasa/metabolismo , Lípidos/sangre , Hígado/metabolismo , Receptores X del Hígado/metabolismo , Ratones Endogámicos C57BL , Obesidad/sangre , Obesidad/etiología , Saponinas/aislamiento & purificación , Factores de Tiempo , Regulación hacia Arriba , Aumento de Peso/efectos de los fármacosRESUMEN
Nonalcoholic fatty liver disease is recognized as the most commonly occurring chronic liver disease. Liver X receptor α (LXRα) and sterol regulatory element-binding protein (SREBP)-1c play a central role in de novo fatty acid synthesis. This study investigated pharmacological effects of nectandrin B, a lignan isolated from nutmeg extract, on hepatic lipogenesis stimulated by LXRα-SREBP-1c-mediated pathway and the possible molecular basis. The reporter gene assay revealed that nectandrin B completely represses LXRα activity enhanced by a synthetic LXRα ligand (T0901317) in HepG2 cells. The inhibitory effect was further supported by the suppression of mRNA expression of LXRα target genes, SREBP-1c and LXRα itself. Nectandrin B also inhibited the increase in SREBP-1c expression promoted by insulin plus high glucose, major contributors to hepatic lipid accumulation. LXRα-SREBP-1c-mediated induction of acetyl-CoA carboxylase 1 and fatty acid synthase, major genes for de novo lipogenesis, was suppressed by nectandrin B. Moreover, Oil Red O staining showed that nectandrin B notably attenuates LXRα-induced lipid accumulation. AMP-activated protein kinase (AMPK) inhibits the activities of LXRα and SREBP-1c. Nectandrin B strongly activated AMPK signaling in HepG2 cells. Taken together, the suppressive effects of nectandrin B on lipogenic gene expression and lipid accumulation in hepatocytes may be due to its inhibitory effect on the LXRα-SREBP-1c pathway presumably via AMPK activation. These results suggest the potential of nectandrin B as a therapeutic candidate for fatty liver disease.